Clinical Trial Update: Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of cabazitaxel plus daily prednisolone in patients with hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Prednisolone (Prednisolone)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED